Bishop J F, Joshua D E, Lowenthal R M, Kronenberg H, Whiteside M G, Cobcroft R, Dodds A, Wolf M, Manoharan A
Aust N Z J Med. 1986 Feb;16(1):48-51. doi: 10.1111/j.1445-5994.1986.tb01115.x.
The combination cytosine arabinoside (ara-C), daunorubicin, and VP 16-213 was studied in 28 patients with acute non-lymphocytic leukemia to define the toxicity of the combination and assess its efficacy. Of 21 previously untreated patients, 16 (76%) achieved a complete response (CR) with the median remission duration not reached but exceeding 25 weeks. For CR patients, the median number of days with neutrophils less than 500/microliter was 19. The median survival for patients with CR is 60 weeks. Two of seven previously treated patients achieved CR for 11 weeks and in excess of 36 weeks, respectively. At the initial VP16-213 dose of 100 mg m-2 per day for seven days, severe stomatitis was seen in 38% of courses but was less with dose reduction to 75 mg m-2 per day for seven days. Other toxicity was similar to previous experience with ara-C and daunorubicin alone.
对28例急性非淋巴细胞白血病患者研究了阿糖胞苷（ara-C）、柔红霉素和依托泊苷（VP 16-213）联合用药情况，以确定该联合用药的毒性并评估其疗效。在21例既往未接受过治疗的患者中，16例（76%）获得完全缓解（CR），中位缓解持续时间未达到但超过25周。对于CR患者，中性粒细胞计数低于500/微升的中位天数为19天。CR患者的中位生存期为60周。7例既往接受过治疗的患者中有2例分别获得了11周和超过36周的CR。在初始VP16-213剂量为每日100mg/m²，共7天时，38%的疗程出现严重口腔炎，但剂量减至每日75mg/m²，共7天时则较少出现。其他毒性与既往单独使用阿糖胞苷和柔红霉素的经验相似。
